Taxis Pharmaceuticals Overview

  • Founded
  • 2009

Founded
  • Status
  • Private

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $3.2M

  • Investors
  • 3

Taxis Pharmaceuticals General Information

Description

Developer of antibiotics and antiviral drugs designed to address the health crisis of antimicrobial resistance. The company's platform offers antibiotics and therapeutic agents that employ novel mechanisms of action distinct from those currently in clinical use and target multidrug-resistant bacterial pathogens, enabling hospitals to treat MRSA (Methicillin-Resistant Staphylococcus Aureus) affected patients effectively.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Drug Delivery
Primary Office
  • 9 Deerpark Drive
  • Monmouth Junction, NJ 08852
  • United States

Taxis Pharmaceuticals Timeline

2019202020212022
Financing Round

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Taxis Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Grant 14-Jan-2020 $3.2M 000.00 Completed Generating Revenue
6. Later Stage VC 01-Jan-2020 00.00 Cancelled Generating Revenue
5. Later Stage VC (Series B) 09-Jan-2019 00.000 000.00 000.00 Completed Generating Revenue
4. Angel (individual) 25-Sep-2017 000 Cancelled Generating Revenue
3. Later Stage VC (Series B) 10-Mar-2017 00.00 000.00 0000 Completed Generating Revenue
2. Early Stage VC (Series A) 13-Apr-2015 $6.5M $6.74M 000.00 Completed Generating Revenue
1. Angel (individual) 19-Apr-2010 $237K $237K Completed Startup
To view Taxis Pharmaceuticals’s complete valuation and funding history, request access »

Taxis Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series A 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
To view Taxis Pharmaceuticals’s complete cap table history, request access »

Taxis Pharmaceuticals Patents

Taxis Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3058183-A1 Synthetic processes and synthetic intermediates Pending 30-Mar-2017 0000000000
EP-3600298-A4 Synthetic processes and synthetic intermediates Pending 30-Mar-2017 0000000000 0
EP-3600298-A1 Synthetic processes and synthetic intermediates Pending 30-Mar-2017 0000000000
US-10774093-B2 Synthetic processes and synthetic intermediates Active 30-Mar-2017 0000000000 00
US-20200055870-A1 Synthetic processes and synthetic intermediates Active 30-Mar-2017 A61P31/04
To view Taxis Pharmaceuticals’s complete patent history, request access »

Taxis Pharmaceuticals Executive Team (4)

Name Title Board Seat Contact Info
Gregory Mario Co-Founder, Chief Executive Officer, President and Board Member
Daniel Pilch Ph.D Co-Founder
Henry Chambers MD Scientific Advisor
Edmond LaVoie Ph.D Co-Founder
To view Taxis Pharmaceuticals’s complete executive team members history, request access »

Taxis Pharmaceuticals Board Members (6)

Name Representing Role Since
Christopher Cimarusti Taxis Pharmaceuticals Board Member 000 0000
Ernest Mario Ph.D Taxis Pharmaceuticals Board Member 000 0000
Gail McIntyre Ph.D Self Board Member 000 0000
Gregory Mario Taxis Pharmaceuticals Co-Founder, Chief Executive Officer, President and Board Member 000 0000
S. David Kimball Ph.D Self Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Taxis Pharmaceuticals Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
CARB-X University 000 0000 000000 0
Eagles Ketch Asset Manager Minority 000 0000 000000 0
Ithaka Partners Growth/Expansion Minority 000 0000 000000 0
To view Taxis Pharmaceuticals’s complete investors history, request access »